MiNK Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: INKT · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1840229
Sentiment: neutral
Topics: shareholder-vote, corporate-action, sec-filing
TL;DR
MiNK Therapeutics is holding a shareholder vote on June 18, 2025.
AI Summary
MiNK Therapeutics, Inc. filed an 8-K on June 18, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as AgenTus Therapeutics, Inc., is incorporated in Delaware and has its principal executive offices in New York. This filing indicates a shareholder meeting or vote is taking place.
Why It Matters
This filing signals that MiNK Therapeutics is engaging in a formal process of seeking shareholder approval for significant corporate actions, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not an announcement of a significant event like a merger or financial distress.
Key Numbers
- 001-40908 — SEC File Number (Identifies the company's filing history with the SEC.)
- 212 994-8250 — Business Phone (Contact number for the company's principal executive offices.)
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former Company Name
- June 18, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Principal Executive Offices City
FAQ
What specific matters are being submitted to a vote of MiNK Therapeutics' security holders?
The filing indicates that matters are being submitted to a vote, but the specific details of these matters are not provided in the provided text.
When was MiNK Therapeutics, Inc. formerly known as AgenTus Therapeutics, Inc.?
The date of the name change from AgenTus Therapeutics, Inc. to MiNK Therapeutics, Inc. was January 12, 2021.
What is the primary business of MiNK Therapeutics, Inc. according to its SIC code?
MiNK Therapeutics, Inc. is classified under SIC code 2836, which pertains to Biological Products (No Diagnostic Substances).
Where are MiNK Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of MiNK Therapeutics, Inc. are located at 149 Fifth Avenue, Suite 500, New York, New York, 10010.
What is the filing date of this 8-K report?
This 8-K report was filed as of June 18, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding MiNK Therapeutics, Inc. (INKT).